GSK Oncology Mega-Acquisition
GSK's $10.6 billion acquisition of Nuvalent marks its largest deal in eight years, signaling aggressive re-entry into oncology and triggering a wave of repricing across cancer-focused biotech peers including Incyte and Johnson & Johnson as investors reassess competitive positioning and M&A premium potential across the sector.
股票
相关资产
| 资产 | 价格 | 24小时涨跌 | 板块 |
|---|---|---|---|
LLYEli Lilly and Company | $1,231.4 | +2.21% | healthcare |
GILDGilead Sciences Inc | $134.77 | +4.39% | healthcare |
JNJJohnson & Johnson | $267.46 | +2.71% | healthcare |
GSKGSK plc | $53.22 | +0.83% | general |
最新市场快讯
GSK 110亿美元收购Nuvalent：杠杆情景分析、并购套利价差及行业重估
GSK拟以110亿美元现金收购Nuvalent，溢价40%，目标是两个处于后期阶段、已提交FDA审查的肺癌药物；GSK差价合约（CFD）交易者将面临2026年9月/11月的二元FDA催化剂，而Nuvalent现已成为一个接近124美元的封顶并购套利工具。
GSK
2026-06-11
相关板块
准备好交易了吗？
在 CoinUnited.io 以最高 2,000 倍杠杆交易与「GSK Oncology Mega-Acquisition」主题相关的资产。
在 CoinUnited.io 开始交易 →